MedPath

Omega-6/Omega-3 Ratio and Neural Development in Preterm Infants.

Phase 1
Completed
Conditions
Impaired Psychomotor Development
Interventions
Dietary Supplement: Preterm infants formula
Registration Number
NCT02339727
Lead Sponsor
Ayham alshweki
Brief Summary

It's known that Docosahexaenoic acid DHA and all Polyunsaturated Fatty Acids PUFA are important in neurodevelopment of term and preterm infants. This study tried to determine the utility of a balanced contribution of DHA and Arachidonic acid AA (omega-6/omega-3) in milk formula, with a ratio similar to that found in breastfeeding, equal to 2, in very premature infants less than 1500 grams and / or less than 32 weeks of gestational age. To evaluate values of fatty acids they have in blood and psychomotor development they achieve.

Detailed Description

The study took place in a single-center; it is a prospective randomized study of preterm infants less than 1500 grams and/or less than 32 weeks gestational age, admitted to the Neonatal Intensive Care Unit in the University Clinical Hospital of Santiago de Compostela. They were recruited for a period of 14 months (from July 2010 to august 2011) and followed from birth until 2 years of life.

40 children were included and followed in the study. Patients will be assigned randomly into two groups depending on the type of formula they are receiving. The group A of children will receive a formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2. And group B will receive other formula with DHA and ARA, but with a ratio of 1/1.

The classification of group A and B was made by simple random way; one birth in every group, continuously.

Implementation of breastfeeding will be promoted and will be fortified after 7 days of life, when the total amount of breast milk will be more than 1/2 of the total.

When breastfeeding will be insufficient or nonexistent, special formulas for premature babies will be given

During the follow-up of patients, will be measured:

1. - Levels of fatty acids in blood in the first week of life, 3 months, 6 months and 12 months.The determination will be carried out in collaboration with the Hospital de Cruces, Bilbao, Spain.

2. - Evaluation of psychomotor development by Brunet-Lezine scale at 2 years of corrected age.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Living infants who were less than 1500 grams and/or less than 32 weeks gestational age, and whose parents accepted and subscribed the informed consent

Exclusion Criteria
  • Preterm infants with any malformation or deformation.
  • Extreme preterm infants with gestational age less than 25 weeks.
  • Infants whose parents couldn't follow up their children in our study center.
  • Preterm infants who had a severe intra ventricular hemorrhage (more than grade 2).
  • Premature infants who had severe periventricular leukomalacia (more than grade 2) because the latest two conditions can affect neurodevelopment.
  • Finally, we excluded neonates who don't need supplementary milk nutrition, i.e. children with breastfeeding only.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Omega-6/omega-3=2/1 milk formulaPreterm infants formulaPreterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
Omega-6/omega-3=1/1 milk formulaPreterm infants formulapreterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
Primary Outcome Measures
NameTimeMethod
Levels of fatty acids in bloodfrom July 2010 to august 2012 (from the birth to 1 years old)

Levels of fatty acids in blood in the first week of life, 3 months, 6 months and 12 months of live

Secondary Outcome Measures
NameTimeMethod
Psychomotor developmentfrom september 2012 to november 2013 (at two years of corrected age)

Evaluation of psychomotor development by making Brunet-Lezine scale at 2 years of corrected age.

© Copyright 2025. All Rights Reserved by MedPath